Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Long-term follow-up of two patients with retained intraosseous sternal needles.

Hodgetts JM, Johnston A, Kendrew J.

J R Army Med Corps. 2017 Jun;163(3):221-222. doi: 10.1136/jramc-2016-000699. Epub 2017 Mar 1.

PMID:
28249956
2.

Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.

Hargreaves A, Bigley A, Price S, Kendrew J, Barry ST.

J Appl Toxicol. 2017 Aug;37(8):902-912. doi: 10.1002/jat.3438. Epub 2017 Feb 10.

PMID:
28186326
3.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

Pommier AJ, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST.

Cell Metab. 2016 Jan 12;23(1):77-93. doi: 10.1016/j.cmet.2015.10.015. Epub 2015 Nov 25.

4.

Tumor stromal phenotypes define VEGF sensitivity--response.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. No abstract available.

5.

Therapeutic targeting of integrin αvβ6 in breast cancer.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug.

6.

Delayed haemoptysis from explosive device fragments.

Johnston AM, West AT, Kendrew JM, Steyn RS, Kalkat MS, Graham TR.

Lancet. 2013 Sep 28;382(9898):1152. doi: 10.1016/S0140-6736(13)61651-7. No abstract available.

PMID:
24075055
7.

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2013 Dec 15;19(24):6943-56. doi: 10.1158/1078-0432.CCR-13-1637. Epub 2013 Sep 12.

8.

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26.

PMID:
23355042
9.

Severe open tibial fractures in combat trauma: management and preliminary outcomes.

Penn-Barwell JG, Bennett PM, Fries CA, Kendrew JM, Midwinter MJ, Rickard RF.

Bone Joint J. 2013 Jan;95-B(1):101-5. doi: 10.1302/0301-620X.95B1.30580.

PMID:
23307681
10.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST.

Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29.

PMID:
23108397
11.

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.

Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.

12.

The open blast pelvis: the significant burden of management.

Ramasamy A, Evans S, Kendrew JM, Cooper J.

J Bone Joint Surg Br. 2012 Jun;94(6):829-35. doi: 10.1302/0301-620X.94B6.28359.

PMID:
22628601
13.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4111-6. doi: 10.1016/j.bmcl.2012.04.063. Epub 2012 Apr 21.

PMID:
22575869
14.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4117-21. doi: 10.1016/j.bmcl.2012.04.061. Epub 2012 Apr 21.

PMID:
22572578
15.

Modern military surgery: lessons from Iraq and Afghanistan.

Brown KV, Guthrie HC, Ramasamy A, Kendrew JM, Clasper J.

J Bone Joint Surg Br. 2012 Apr;94(4):536-43. doi: 10.1302/0301-620X.94B4.28602. Review.

PMID:
22434472
16.

Fixed flexion deformity following total knee arthroplasty. A prospective study of the natural history.

Quah C, Swamy G, Lewis J, Kendrew J, Badhe N.

Knee. 2012 Oct;19(5):519-21. doi: 10.1016/j.knee.2011.09.003. Epub 2011 Oct 13.

PMID:
21996572
17.

Radiological predictive factors in the healing of displaced intracapsular hip fractures. A clinical study of 404 cases.

Parker MJ, Kendrew J, Gurusamy K.

Hip Int. 2011 Jul-Aug;21(4):393-8. doi: 10.5301/HIP.2011.8578.

PMID:
21818738
18.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

19.

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.

Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, Kang JS, Barry ST.

Mol Cancer Ther. 2011 May;10(5):770-83. doi: 10.1158/1535-7163.MCT-10-0876. Epub 2011 Mar 9.

20.

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC.

Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6.

21.
22.

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST.

Mol Cancer Ther. 2007 Aug;6(8):2198-208.

23.

Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).

Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR.

NMR Biomed. 2008 Jan;21(1):42-52. Erratum in: NMR Biomed. 2008 Mar;21(3):302.

PMID:
17458919
24.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4908-12. Epub 2006 Jun 27.

PMID:
16806916
25.

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

Hennequin LF, Ballard P, Boyle FT, Delouvrié B, Ellston RP, Halsall CT, Harris CS, Hudson K, Kendrew J, Pease JE, Ross HS, Smith P, Vincent JL.

Bioorg Med Chem Lett. 2006 May 15;16(10):2672-6. Epub 2006 Mar 3.

PMID:
16516473
26.

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M.

Xenobiotica. 2006 Jan;36(1):29-39.

PMID:
16507511
27.

Reverse obliquity and transverse fractures of the trochanteric region of the femur; a review of 101 cases.

Brammar TJ, Kendrew J, Khan RJ, Parker MJ.

Injury. 2005 Jul;36(7):851-7. Epub 2005 Apr 2.

PMID:
15949487
28.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

29.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC.

Mol Cancer Ther. 2005 Apr;4(4):641-9.

30.

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR.

Clin Cancer Res. 2004 Dec 15;10(24):8587-93.

31.

The role of anxiety level, coping styles, and cycle phase in menstrual distress.

Sigmon ST, Whitcomb-Smith SR, Rohan KJ, Kendrew JJ.

J Anxiety Disord. 2004;18(2):177-91.

PMID:
15033215
32.

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.

Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR.

Br J Cancer. 2003 Nov 17;89(10):1889-95.

33.

Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.

Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC.

Magn Reson Imaging. 2003 Jun;21(5):475-82.

PMID:
12878256
34.

The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study.

Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC.

Histopathology. 2003 Jul;43(1):33-9.

PMID:
12823710
35.

ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.

Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO.

Microcirculation. 2002 Dec;9(6):513-22.

PMID:
12483548
36.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.

37.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.

J Med Chem. 2002 Mar 14;45(6):1300-12.

PMID:
11881999
38.

Correlates of sleep quality in persons with HIV disease.

Nokes KM, Kendrew J.

J Assoc Nurses AIDS Care. 2001 Jan-Feb;12(1):17-22.

PMID:
11211669
39.

Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis.

Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E.

Lab Invest. 2000 Aug;80(8):1195-205.

PMID:
10950110
40.

Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport.

Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, Witters LA, Ismail-Beigi F.

Arch Biochem Biophys. 2000 Aug 15;380(2):347-52.

PMID:
10933890
41.

Exploring the complexity of sleep disturbances in persons with HIV/AIDS.

Nokes KM, Chidekel JH, Kendrew J.

J Assoc Nurses AIDS Care. 1999 May-Jun;10(3):22-9.

PMID:
10707693
42.

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF.

Cancer Res. 2000 Feb 15;60(4):970-5.

43.

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.

J Med Chem. 1999 Dec 30;42(26):5369-89.

PMID:
10639280
44.

Development of an HIV educational needs assessment tool.

Nokes KM, Kendrew J, Rappaport A, Jordan D, Rivera L.

J Assoc Nurses AIDS Care. 1997 Nov-Dec;8(6):46-51.

PMID:
9356966
45.

Sleep quality in people with HIV disease.

Nokes KM, Kendrew J.

J Assoc Nurses AIDS Care. 1996 May-Jun;7(3):43-50.

PMID:
8816356
46.

Alternative/complementary therapies used by persons with HIV disease.

Nokes KM, Kendrew J, Longo M.

J Assoc Nurses AIDS Care. 1995 Jul-Aug;6(4):19-24.

PMID:
7495988
47.

Development of an HIV assessment tool.

Nokes KM, Wheeler K, Kendrew J.

Image J Nurs Sch. 1994 Summer;26(2):133-8.

PMID:
8063320
48.

Loneliness in veterans with AIDS and its relationship to the development of infections.

Nokes KM, Kendrew J.

Arch Psychiatr Nurs. 1990 Aug;4(4):271-7.

PMID:
2241247
49.

The European Molecular Biology laboratory.

Kendrew J.

Endeavour. 1980;4(4):166-70. No abstract available.

PMID:
6161000
50.

Some remarks on the history of molecular biology.

Kendrew JC.

Biochem Soc Symp. 1970;30:5-10. No abstract available.

PMID:
4923830

Supplemental Content

Loading ...
Support Center